Product Name: LATS1 (911-918) pT913+pY916
Product Number: PE-04AVX01
| Size: | $US |
Peptide Name: LATS1 (911-918) pT913+pY916
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T913 and Y916 are not confirmed phosphosites and if they were, they would be predicted to inhibit phosphotransferase activity when phosphorylated. These phosphosits are located in the kinase activation loop between catalytic subdomains VII and VIII.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VG(pT)PN(pY)IA
Peptide Modifications N Terminus: Free amino
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T913 and Y916 are not confirmed phosphosites and if they were, they would be predicted to inhibit phosphotransferase activity when phosphorylated. These phosphosits are located in the kinase activation loop between catalytic subdomains VII and VIII.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VG(pT)PN(pY)IA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Scientific Background: LATS1 (WARTS) is a protein-serine/threonine kinase of the AGC group and NDR family. LATS1 appears to be a tumour suppressor protein (TSP), although it undergoes a typical rate of bystander mutations in human cancers. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. It also promotes apoptosis by activating the transcription of BAX, caspase 3 and p53, and inhibiting the oncogene actions of YAP1. It can phosphorylate and inactivate the YAP1 and inhibit its translocation to the nucleus for transcription of genes important for proliferation and migration. NUAK1 and NUAK2 mediated phosphorylation of LATS1 can be inhibited with a LATS1 mutation of S464A. Inhibition of LATS1-YAP1 interaction can occur with a Y559F mutation. The K734A mutation can abrogate kinase phosphotransferase activity, lack of p53 translation, increased time for mitosis, autophosphorylation, and increased ploidy. LATS1 also negatively regulates the G2/M transition by downregulating CDK1 phosphotransferase activity. M669I and R806P mutations have been associated with lung adenocarcinoma and lung large cell carcinoma, respectively. Decreased LATS1 expression due to hypermethylation of the promoter have been associated with breast cancer, acute lymphoblastic leukemia, ovarian cancer, and astrocytoma. However, the very low frequency of reported somatic mutations in this protein indicates that it may function as a tumour requiring protein (TRP) in many human tumours. LATS1 is activated by phosphorylation at S909 and T1079.
© Kinexus Bioinformatics Corporation 2017